These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 20066139)

  • 1. Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease.
    Ross RL; Serock MR; Khalil RA
    Curr Cardiol Rev; 2008 Nov; 4(4):309-22. PubMed ID: 20066139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
    Koledova VV; Khalil RA
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.
    Khalil RA
    Biochem Pharmacol; 2013 Dec; 86(12):1627-42. PubMed ID: 24099797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex hormones, vascular function and the outcome of hormone replacement therapy in cardiovascular disease.
    Khalil RA
    Future Cardiol; 2007 May; 3(3):283-300. PubMed ID: 19804220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research into Specific Modulators of Vascular Sex Hormone Receptors in the Management of Postmenopausal Cardiovascular Disease.
    do Nascimento GR; Barros YV; Wells AK; Khalil RA
    Curr Hypertens Rev; 2009 Nov; 5(4):283-306. PubMed ID: 20694192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex steroids and vascular responses in hypertension and aging.
    Qiao X; McConnell KR; Khalil RA
    Gend Med; 2008; 5 Suppl A():S46-64. PubMed ID: 18395683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex hormones as potential modulators of vascular function in hypertension.
    Khalil RA
    Hypertension; 2005 Aug; 46(2):249-54. PubMed ID: 15983238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause.
    Serock MR; Wells AK; Khalil RA
    Recent Pat Cardiovasc Drug Discov; 2008 Nov; 3(3):165-86. PubMed ID: 18991792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular effects of estrogenic menopausal hormone therapy.
    Reslan OM; Khalil RA
    Rev Recent Clin Trials; 2012 Feb; 7(1):47-70. PubMed ID: 21864249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease.
    Masood DE; Roach EC; Beauregard KG; Khalil RA
    Curr Drug Metab; 2010 Oct; 11(8):693-714. PubMed ID: 21189141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential approaches to enhance the effects of estrogen on senescent blood vessels and postmenopausal cardiovascular disease.
    Khalil RA
    Cardiovasc Hematol Agents Med Chem; 2010 Jan; 8(1):29-46. PubMed ID: 20210774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproductive hormones and cardiovascular disease mechanism of action and clinical implications.
    Wagner JD; Kaplan JR; Burkman RT
    Obstet Gynecol Clin North Am; 2002 Sep; 29(3):475-93. PubMed ID: 12353669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender, sex hormones, and vascular tone.
    Orshal JM; Khalil RA
    Am J Physiol Regul Integr Comp Physiol; 2004 Feb; 286(2):R233-49. PubMed ID: 14707008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels.
    Smiley DA; Khalil RA
    Curr Med Chem; 2009; 16(15):1863-87. PubMed ID: 19442151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women.
    Saitta A; Altavilla D; Cucinotta D; Morabito N; Frisina N; Corrado F; D'Anna R; Lasco A; Squadrito G; Gaudio A; Cancellieri F; Arcoraci V; Squadrito F
    Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1512-9. PubMed ID: 11557681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users.
    Oger E; Alhenc-Gelas M; Plu-Bureau G; Mennen L; Cambillau M; Guize L; Pujol Y; Scarabin P
    Thromb Res; 2001 Jan; 101(2):35-43. PubMed ID: 11342204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender differences in the regulation of vascular tone.
    Thompson J; Khalil RA
    Clin Exp Pharmacol Physiol; 2003; 30(1-2):1-15. PubMed ID: 12542447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hormone replacement therapy in matrix metalloproteinase expression and intimal hyperplasia development after vascular injury.
    Mountain DJ; Freeman MB; Kirkpatrick SS; Cook RB; Chalk JE; Stevens SL; Goldman MH; Grandas OH
    Ann Vasc Surg; 2013 Apr; 27(3):337-45. PubMed ID: 23088810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.